Selective cyclooxygenase-2 (COX-2) inhibitor (IC50 values are 15 and 0.04 μM for COX-1 and COX-2 respectively). Anti-inflammatory with shorter plasma half-life in vivo than SC 58121 (Cat. No. 2895). Displays chemopreventive activity in in vivo tumor models.
Sold for research purposes under agreement from Pfizer Inc.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 381.37. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.62 mL||13.11 mL||26.22 mL|
|5 mM||0.52 mL||2.62 mL||5.24 mL|
|10 mM||0.26 mL||1.31 mL||2.62 mL|
|50 mM||0.05 mL||0.26 mL||0.52 mL|
References are publications that support the products' biological activity.
Penning et al (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J.Med.Chem. 40 1347 PMID: 9135032
DeWitt (1999) Cox-2-selective Inhibitors: the new super aspirins. Mol.Pharmacol. 55 625 PMID: 10101019
Harris et al (2000) Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 60 2101 PMID: 10786667
If you know of a relevant reference for Celecoxib, please let us know.
View Related Products by Product Action
Keywords: Celecoxib, supplier, Selective, cyclooxygenase-2, COX-2, inhibitors, inhibits, Oxygenases, Oxidases, SC58635, Pfizer, SC, 58635, Celebrex, Cyclooxygenase, Cyclooxygenase, Tocris Bioscience
Citations for Celecoxib
Citations are publications that use Tocris products.
Currently there are no citations for Celecoxib. Do you know of a great paper that uses Celecoxib from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.